Mutation profiling by next-generation sequencing (NGS) has advanced the understanding of acute myeloid leukemia (AML) molecular pathogenesis. NGS has been incorporated into the International Consensus Classification (ICC) for disease classification and the European LeukemiaNet (ELN) 2022 (ELN2022) for risk classification.
Researchers conducted a retrospective study to compare disease subtypes between the 4th edition of the WHO classification (WHO-4) and the ICC and further compare disease risk classifications using the ELN2017 and the ELN2022.
They used targeted sequencing of bone marrow samples from 91 patients with AML.
The results showed that entities under AML with recurrent genetic abnormalities were well-established, with almost no change from the WHO-4 to the ICC; 16.7% of AML cases not otherwise specified in the WHO-4 were reclassified as AML with mutated TP53. Another 36.7% were reclassified as AML with myelodysplasia-related gene mutations or cytogenetic abnormalities, according to the ICC. The ELN2017 and ELN2022 showed no difference in concordance indexes in multivariate Cox regression analysis for PFS and OS.
They concluded that the superiority of the ELN2022 over the ELN2017 could not be, and further investigation, including multicenter prospective studies, is needed.
Souce: link.springer.com/article/10.1007/s12185-024-03841-w
Originally Published By Physician’s Weekly. Reused by Medicom Medical Publishers with permission.
©2024 Physician’s Weekly. All rights reserved. No works may be reproduced without expressed written consent from Physician’s Weekly. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by Physician’s Weekly.
Posted on
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com